AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
HSTM

HealthStream Inc. Common Stock (HSTM) fair value

Healthcare · Health Information Services · NASDAQ · United States
$35.16+1.65%
Market cap $1.1BNext earnings 2026-11-02Updated Oct 19, 2026
Add earnings to calendarGoogle
Our verdict
Trades 71% above our fair value
Price
$35.16
Model fair valueConfidence: good
$20.54
Model range
$12.59 to $25.44
Fair value $20.54
Price $35.16
4 models fit HealthStream Inc. Common Stock and they disagree: 1 of 4 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Large premium(i)Bronze55
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionHealthStream Inc. Common Stock (HSTM)
Fair value (4 models)
$20.54
ACCE price target
$32.00
Rating
Overvalued
Horizon
12 months
Fair value published on 19 Oct 2026, 17:05 CEST; previously $25.58 since 15 Oct 2026, 00:00 CEST.
ACCE price target published on 13 Oct 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 17:05 CEST.
Price used: $35.16 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
71.1% above
-41.6% to fair value
ACCE score
71
out of 100
Analysts
33% buy
6 covering
P/E
46.7x
forward 33.8x
1-year return
+32.7%
Dividend yield
0.39%

HealthStream Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

HealthStream sells workforce management and credentialing software to hospitals and health systems, including scheduling, competency tracking and credentialing tools used to keep clinical staff compliant and deployed. Its moat comes from being embedded in the daily operations of its customers, where switching means re-validating thousands of clinician credentials and retraining staff, which makes churn sticky. Revenue is growing 12.5% with a 65.1% gross margin, and operating margin of 9.9% shows the business is now converting that growth into profit rather than just spending it. At a 46.9 trailing P/E falling to 33.8 on forward earnings, the market is pricing in continued margin expansion, so the question for a deeper look is whether operating leverage on the existing base can carry the multiple. The 6.0% return on equity and absence of index membership suggest a small, under-followed name where the earnings trajectory matters more than the current print.

AI-assisted·How I use AIWritten Oct 18, 2026

AI research notes

AI-assisted·How I use AIWritten Oct 19, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Revenue grew 12.5% year over year, well ahead of its 4.4% average annual pace over five years.
  • Free cash flow over the last twelve months reached $60M, and the share count fell 1.3% last year.
  • Analysts' mean price target of $35.00 sits 5.6% above the current share price.
Why it could disappoint
  • The stock trades at a trailing P/E of 46.0x, far above the sector median forward P/E of 24.2x.
  • Return on invested capital of 4.1% and a net margin of 6.6% show thin returns for a stock priced at this multiple.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 2, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where HSTM's valuation models land
Price
$35.16
Model fair value
$20.54
Model range
$12.59 to $25.44
Fair value $20.54
Price $35.16
The price is above the whole model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bearish33% buy · 6 covering analysts
● Strong buy 2● Buy 0● Hold 4● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+6.1%
1 month
+22.3%
3 months
+29.6%
6 months
+65.0%
YTD
+52.4%
1 year
+32.7%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
19 Oct 2026, 17:05 CESTFair value$20.54$25.58$33.13
19 Oct 2026, 17:05 CESTRatingOvervaluedfirst publication$33.13
15 Oct 2026, 00:00 CESTFair value$25.58$25.05$33.75
13 Oct 2026, 00:00 CESTACCE price target$32.00first publication$33.13
10 Oct 2026, 00:00 CESTFair value$25.05$24.21$32.47
29 Sept 2026, 00:00 CESTFair value$24.21$24.59$29.10
19 Sept 2026, 00:00 CESTFair value$24.59$25.96$29.19
16 Sept 2026, 00:00 CESTFair value$25.96$26.31$29.63
5 Sept 2026, 00:00 CESTFair value$26.31$27.53$29.74
3 Sept 2026, 00:00 CESTFair value$27.53$27.04$29.67

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full HSTM page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth68Value49Quality71Momentum97Total71
Valuation
Trailing P/E
46.7x
Forward P/E
33.8x
PEG
1.65
P/B
2.47x
EV / Revenue
2.6x
Book value/sh
$12.20
Enterprise value
$827M
Profitability
ROE
6.0%
FCF yield
5.63%
ROIC
4.1%
Health and risk
Debt / equity
0.04
Dividend yield
0.39%
Beta
0.42

Price

+33.6% · 1Y

Ask anything about HSTM

Answered from HealthStream Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 50% of peers
low 0.0x46.7xhigh 79.1x
ROEbetter than 100% of peers
low -13%6%high 6%
Div yieldbetter than 100% of peers
low 0.0%0.4%high 0.4%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
HSTM HealthStream Inc. Common Stock$35.16$2171% above46.7x6.0%7171
TDOC Teladoc Health Inc. Common Stock$6.34----13.0%4338
OMDA Omada Health Inc. Common Stock$18.95--79.1x1.8%4347
GDRX GoodRx Holdings Inc. Class A Common Stock$3.54$535% below70.8x2.5%5451
TALK Talkspace Inc. Common Stock$5.25---0.2%2752
PHR Phreesia Inc. Common Stock$12.70$1619% below74.7x3.1%5567
CERT Certara Inc. Common Stock$10.33$822% above--2.2%4744

Sector report card

Where HSTM ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Sep 15, 2026
    HealthStream Completes $40 Million Private Placement of Its Common Stock
  • Business Wire•Sep 14, 2026
    HealthStream Defines a New Enterprise Category Alongside the EHR and ERP, the Enterprise Clinical Workforce Platform (ECWP)
  • Business Wire•Aug 11, 2026
    Humana Healthy Horizons in Indiana Collaborates with HealthStream to Expand and Strengthen Home Care Workforce
3 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 23
Form 4Insider transactionPeriod 2026-10-23
View on SEC →
September 2026
Sep 29
Form 4Insider transactionPeriod 2026-09-29
View on SEC →
Sep 29
Form 4Insider transactionPeriod 2026-09-29
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR